ALZ 801

Drug Profile

ALZ 801

Alternative Names: ALZ-801; BLU-8499; NRM-8499; Tramiprosate prodrug

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator BELLUS Health
  • Class Alkanesulfonic-acids; Antidementias; Neuroprotectants; Propylamines; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 25 Jul 2016 Adverse events and Pharmacokinetics data from two phase Ib trials in Healthy volunteers presented at Alzheimer's Association Intenrational Conference (AAIC-2016)
  • 01 Jul 2016 Alzheon completes two phase Ib trials for Alzheimer's disease in USA (700266591; 700266592)
  • 11 Mar 2016 Pharmacodynamics and Adverse events data from two prior independent phase III trial of tramiprosate in Alzheimer’s disease released by Alzheon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top